Bcl-2-related protein A1 (BCL2A1) (BCL2A1)

Bcl-2-related protein A1 (BCL2A1), also known as Bfl-1, is an anti-apoptotic member of the BCL-2 family that plays a critical role in regulating the intrinsic apoptotic pathway [1, 4]. It functions by sequestering pro-apoptotic proteins such as Bax, Bak, and BH3-only proteins (e.g., Bim, Puma), thereby preventing mitochondrial outer membrane permeabilization and the subsequent release of cytochrome c [1, 2, 13]. BCL2A1 is primarily expressed in the hematopoietic system and is a direct transcriptional target of the NF-κB signaling pathway, contributing to the survival of leukocytes during inflammation [1, 3, 9]. In various malignancies, including melanoma, leukemia, and lymphoma, BCL2A1 is frequently overexpressed, where it promotes tumor progression and confers resistance to both conventional chemotherapy and targeted BCL-2 inhibitors like venetoclax [1, 10, 14]. As a result, BCL2A1 is an important therapeutic target, with ongoing research focused on developing specific small-molecule inhibitors and peptide mimetics to sensitize cancer cells to apoptosis [2, 10]. Its role in inflammation and immune cell survival also suggests potential implications in autoimmune and inflammatory diseases [2]. Therapeutic challenges include the shallow nature of its hydrophobic binding groove, which has historically made it difficult to target with small molecules compared to other BCL-2 family members [1, 10]. Monitoring BCL2A1 levels through BH3 profiling or gene expression analysis is a promising strategy for identifying patients likely to benefit from Bfl-1-targeted therapies [11, 14].

Other names

Bfl-1GRSHBPA1BCL2L5ACC-1ACC-2Hemopoietic-specific early response protein

Sequestration of pro-apoptotic proteins (Bax, Bak, BH3-only proteins) to prevent mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release [1, 2, 13].